Crossover Investor

Crossover Investor

An investor who buys an interest in a company at numerous stages in its life cycle. This especially refers to one who buys stock in a company before, during, and after its IPO. The crossover investor's strategy is to buy at different stages of the life cycle to maximize returns. See also: Buy and hold.
References in periodicals archive ?
Stone, managing director for Private Equities and Venture Capital Services, Pacific Growth Equities, LLC This session will uncover the rationale for crossover investor participation from the company and investor's viewpoints as well as the criteria and returns these sophisticated public-private players have for investing.
Led by Lightspeed Venture Partners and Includes Crossover Investor Galleon
Pivotal Asset Management, LLC: Founded in 1998, Pivotal Asset Management, LLC is a leading emerging growth technology crossover investor.
Led by Crossover Investor Integral Capital Partners and Includes Institutional Investor AllianceBernstein LP
Founded in 1998, Pivotal Asset Management, LLC is a leading emerging growth technology crossover investor.
A new investor in 2Wire is Weber Capital, a crossover investor in mid- to late-stage ventures and micro-cap public companies.
In addition to commitments made to Fund VIII, ARCH's relationships with its limited partners, strategic investors, and crossover investors have the potential to support rapid, large-scale funding for pioneering companies like Juno Therapeutics.
We are privileged to have attracted a syndicate of renowned investors with specific expertise in the gastrointestinal market as well as international and crossover investors and we welcome Linda Grais' guidance as she joins our board of directors.
The investment grade structure allowed Argentina to expand its existing emerging markets investor base to attract high-grade and crossover investors in the United States, Europe, and Asia.
We are very pleased to have led Natera's latest round of financing among a distinguished group of crossover investors," said James Healy, MD, PhD, general partner, Sofinnova.